WAYNE, Pa., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for ...
MyChesCo on MSN
Aclaris Therapeutics Unveils Promising Data on ATI-2138, a Novel Dual ITK/JAK3 Inhibitor
WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced significant findings about ATI-2138, a novel ...
WAYNE, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for ...
Aclaris reports potential of ATI-2138 as a dual inhibitor for inflammatory diseases, with promising preclinical and clinical trial results. Aclaris Therapeutics, Inc. has announced the publication of ...
In this model of hair loss, ATI-2138 demonstrated rapid, near-complete, and sustained hair regrowth compared to control and Pfizer Inc.’s (NYSE: PFE) Litfulo (ritlecitinib). ATI-2138 and ritlecitinib ...
that ATI-2138 was generally well tolerated at all doses tested in the trial; that ATI-2138 had dose proportional pharmacokinetics (PK); and a dose-dependent inhibition of both ITK and JAK3 exploratory ...
- ATI-2138 Outperforms Ritlecitinib in Reversal Model of Alopecia Universalis, the Most Severe AA Phenotype - WAYNE, Pa., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a ...
- Primary Endpoint Analysis Confirms Favorable Tolerability Profile of ATI-2138 Without Certain Risks Associated with Other Agents in the Class - - Efficacy Results Show Comparable Outcomes to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results